Clinical Trials Browser

Phase 2 × Hodgkin Disease × idelalisib × Clear all

NCT01393106 2018-11-19

Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Completed

25 enrolled 22 charts

Hodgkin Disease